SQ

YieldMax™ ETFs Announces Monthly Distributions on MSTY (120.57%), CONY (119.30%), NVDY (106.86%), AMDY (65.04%), FBY (61.10%) and Others

Retrieved on: 
Wednesday, April 3, 2024
ARK, MSFT, COIN, Risk, History, Sale, Lovell Minnick Partners, Trust, Investment, ETF, Adviser, AAPL, Funding, TSLA, Capital gain, Prospectus, SQ, PYPL, JPM, NAV, MRNA, AI, NFLX, AMD, GOOY, Government, Unitary state, GOOGL, NVDA, TRUST, XOM, MSTR, AMZN, DIS, Security (finance)

The Distribution Rate is calculated by multiplying an ETF’s Distribution per Share by twelve (12), and dividing the resulting amount by the ETF’s most recent NAV.

Key Points: 
  • The Distribution Rate is calculated by multiplying an ETF’s Distribution per Share by twelve (12), and dividing the resulting amount by the ETF’s most recent NAV.
  • The Distribution Rate and 30-Day SEC Yield are not indicative of future distributions, if any, on the ETFs.
  • Distributions for the ETFs (if any) are variable and may vary significantly from month to month and may be zero.
  • If the Fund does make distributions, the amounts of such distributions will likely vary greatly from one distribution to the next.

Apogee Therapeutics Announces First Participants Dosed in Phase 1 Trial of APG808, its Novel Half-life Extended IL-4Rα Antibody for the Treatment of Chronic Obstructive Pulmonary Disease (COPD) and Other Inflammatory Diseases

Retrieved on: 
Monday, March 25, 2024
I&I, TARC, Atopic dermatitis, Disease, Half-life, Patient, SAN, Heel, IND, Respiratory disease, Asthma, SQ, Clinical trial, Therapy, Safety, Pharmacokinetics, Engineering, Pharmaceutical industry

SAN FRANCISCO and WALTHAM, Mass., March 25, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing differentiated biologics for the treatment of atopic dermatitis (AD), COPD, asthma and other inflammatory and immunology (I&I) indications, today announced that it has initiated dosing of healthy volunteers in its first clinical trial for APG808, a novel subcutaneous (SQ) extended half-life monoclonal antibody (mAb) targeting IL-4Rα, which is being developed as a treatment for people living with moderate-to-severe COPD, asthma and other I&I diseases.

Key Points: 
  • COPD is a progressive respiratory disease that is estimated to affect approximately 10 percent of the global population 40 years of age and older.
  • Despite recent advancements in COPD treatment, a significant number of people continue to suffer and die from the disease.
  • The APG808 Phase 1 trial is designed as a double-blind, placebo-controlled, first-in-human, single-ascending dose trial in healthy volunteers.
  • Importantly, this points to potentially less frequent dosing for patients with COPD, which could significantly improve quality of life.”

Management Mastery LLC Announces Launch of New Leadership Program Designed for Corporate Leaders and Entrepreneurs

Retrieved on: 
Monday, February 26, 2024
Quotient, SQ, Artificial intelligence, Intelligence, Spiritual intelligence, Management

Herndon, Virginia--(Newsfile Corp. - February 26, 2024) - Management Mastery LLC, a leading provider of leadership coaching services , is proud to introduce a groundbreaking leadership program designed to empower Corporate Leaders and Entrepreneurs with a new dimension of intelligence - Spiritual Quotient (SQ) or Spiritual Intelligence.

Key Points: 
  • Herndon, Virginia--(Newsfile Corp. - February 26, 2024) - Management Mastery LLC, a leading provider of leadership coaching services , is proud to introduce a groundbreaking leadership program designed to empower Corporate Leaders and Entrepreneurs with a new dimension of intelligence - Spiritual Quotient (SQ) or Spiritual Intelligence.
  • This unique program, known as the Leadership Operating Systems, encompasses both inner and outer leadership operating systems such as career transition with purposeful alignment, executive brand mastery from a place of authenticity and presence, leadership skills mastery with adaptability, inner operating system upgrades with mindset and emotional energy mastery.
  • It represents a holistic approach that blends spiritual intelligence with emotional and intelligence quotients for an inside-out transformation in leaders.
  • Management Mastery LLC's Leadership Operating Systems program is set to redefine leadership in the corporate landscape, offering a transformative journey towards enhanced effectiveness, impact, and success through the integration of Spiritual Intelligence.

YieldMax™ ETFs Announces Monthly Distributions on NVDY (101.70%), CONY (74.88%), AIYY (70.25%), AMDY (69.08%), MRNY (66.96%) and Others

Retrieved on: 
Tuesday, March 5, 2024
ARK, NFLX, GOOY, SQ, Investment, Sale, ETF, History, Unitary state, GOOGL, Lovell Minnick Partners, JPM, Capital gain, PYPL, COIN, DIS, AAPL, MSFT, AMZN, XOM, AMD, TSLA, NVDA, TRUST, Funding, Adviser, Risk, MRNA, Prospectus, AI, NAV, Government, MSTR, Trust, Security (finance)

The Distribution Rate is calculated by multiplying an ETF’s Distribution per Share by twelve (12), and dividing the resulting amount by the ETF’s most recent NAV.

Key Points: 
  • The Distribution Rate is calculated by multiplying an ETF’s Distribution per Share by twelve (12), and dividing the resulting amount by the ETF’s most recent NAV.
  • The Distribution Rate and 30-Day SEC Yield are not indicative of future distributions, if any, on the ETFs.
  • Distributions for the ETFs (if any) are variable and may vary significantly from month to month and may be zero.
  • If the Fund does make distributions, the amounts of such distributions will likely vary greatly from one distribution to the next.

Apogee Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Tuesday, March 5, 2024
SQ, PD, Injection, I&I, Research, OX40L, Inflammation, Atopic dermatitis, Growth, Asthma, TARC, Chronic obstructive pulmonary disease, IPO, Interim, Safety, Therapy, Pharmacokinetics, Patient, Clinical trial, Half-life, G&A, Pharmaceutical industry

SAN FRANCISCO and WALTHAM, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), asthma and other inflammatory and immunology (I&I) indications, today reported pipeline highlights and fourth quarter and full year 2023 financial results.

Key Points: 
  • “2023 was a momentous year for Apogee with the completion of a successful IPO, initiation of our first clinical program of APG777 in healthy volunteers and the nomination of our second pipeline candidate, APG808,” said Michael Henderson, M.D., Chief Executive Officer of Apogee.
  • Cash Position: Cash, cash equivalents and marketable securities were $395.5 million as of December 31, 2023, compared to $151.9 million as of December 31, 2022.
  • Based on current operating plans, Apogee expects its existing cash, cash equivalents and marketable securities will enable the company to fund its operating expenses into 4Q 2026.
  • Net loss increased primarily as a result of higher R&D and G&A operating expenses as described above, partially offset by higher interest income.

BLOCK ALERT: Bragar Eagel & Squire, P.C. is Investigating Block, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Retrieved on: 
Friday, February 16, 2024
Acquisition, SQ, Telephone, Sale, Mergers and acquisitions, Supreme court, P.C, NSW

NEW YORK, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Block, Inc. (NYSE: SQ) on behalf of long-term stockholders following a class action complaint that was filed against Block on January 31, 2023 with a Class Period from November 4, 2021 to April 4, 2022, including all former shareholders of Afterpay securities who acquired unregistered Block, Inc. Class A common stock (and/or corresponding SQ CHESS Depository Interests (“CDI”)) (“Block Shares” or “Square Securities”) in direct exchange for Afterpay shares pursuant to Block’s January 31, 2022 acquisition and stock-for-stock merger with Afterpay.

Key Points: 
  • NEW YORK, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Block, Inc. (NYSE: SQ) on behalf of long-term stockholders following a class action complaint that was filed against Block on January 31, 2023 with a Class Period from November 4, 2021 to April 4, 2022, including all former shareholders of Afterpay securities who acquired unregistered Block, Inc. Class A common stock (and/or corresponding SQ CHESS Depository Interests (“CDI”)) (“Block Shares” or “Square Securities”) in direct exchange for Afterpay shares pursuant to Block’s January 31, 2022 acquisition and stock-for-stock merger with Afterpay.
  • Our investigation concerns whether the board of directors of Block have breached their fiduciary duties to the company.
  • If you are a long-term stockholder of Block, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at [email protected] , by telephone at (212) 355-4648, or by filling out this contact form .
  • There is no cost or obligation to you.

YieldMax™ ETFs Announces Monthly Distributions on AMDY (87.93%), NFLY (78.50%), NVDY (69.23%), CONY (67.56%), FBY (61.15%) and Others

Retrieved on: 
Tuesday, February 6, 2024
ARK, Prospectus, GOOGL, Risk, Lovell Minnick Partners, NVDA, History, Government, Trust, ETF, MRNA, Investment, AAPL, Unitary state, GOOY, TRUST, AMD, Capital gain, NAV, TSLA, JPM, DIS, SQ, PYPL, COIN, Funding, Sale, Adviser, MSFT, XOM, AMZN, NFLX, Security (finance)

The Distribution Rate is calculated by multiplying an ETF’s Distribution per Share by twelve (12), and dividing the resulting amount by the ETF’s most recent NAV.

Key Points: 
  • The Distribution Rate is calculated by multiplying an ETF’s Distribution per Share by twelve (12), and dividing the resulting amount by the ETF’s most recent NAV.
  • For TSLY, APLY, NVDY, AMZY, FBY, GOOY, NFLY, CONY and SQY, click here .
  • Distributions for the ETFs (if any) are variable and may vary significantly from month to month and may be zero.
  • If the Fund does make distributions, the amounts of such distributions will likely vary greatly from one distribution to the next.

YieldMax™ ETFs Announces Monthly Distributions on MRNY (128.16%), CONY (126.19%), AIYY (84.20%), SQY (83.05%), AMDY (79.08%) and Others

Retrieved on: 
Thursday, January 4, 2024
ARK, NAV, Risk, COIN, Capital gain, Government, AAPL, Investment, Funding, XOM, NFLX, PYPL, TSLA, GOOGL, MSFT, Lovell Minnick Partners, AMD, Trust, DIS, History, NVDA, ETF, GOOY, MRNA, Prospectus, TRUST, Adviser, JPM, Sale, AMZN, SQ, Unitary state, Security (finance)

The Distribution Rate is calculated by multiplying an ETF’s Distribution per Share by twelve (12), and dividing the resulting amount by the ETF’s most recent NAV.

Key Points: 
  • The Distribution Rate is calculated by multiplying an ETF’s Distribution per Share by twelve (12), and dividing the resulting amount by the ETF’s most recent NAV.
  • The Distribution Rate and 30-Day SEC Yield are not indicative of future distributions, if any, on the ETFs.
  • Distributions for the ETFs (if any) are variable and may vary significantly from month to month and may be zero.
  • If the Fund does make distributions, the amounts of such distributions will likely vary greatly from one distribution to the next.

YieldMax™ ETFs Announces Monthly Distributions on CONY (113.67%), SQY (103.19%), TSLY (61.88%), NFLY (52.82%), MSFO (41.63%) and Others

Retrieved on: 
Wednesday, December 6, 2023
ARK, NAV, Risk, COIN, Capital gain, Government, AAPL, Investment, Funding, XOM, NFLX, PYPL, TSLA, GOOGL, MSFT, Lovell Minnick Partners, AMD, Trust, DIS, History, NVDA, ETF, GOOY, MRNA, Prospectus, TRUST, Adviser, JPM, Sale, AMZN, SQ, Unitary state, Security (finance)

For TSLY, APLY, NVDY, AMZY, FBY, GOOY, NFLY, CONY and SQY, click here .

Key Points: 
  • For TSLY, APLY, NVDY, AMZY, FBY, GOOY, NFLY, CONY and SQY, click here .
  • The Distribution Rate and 30-Day SEC Yield are not indicative of future distributions, if any, on the ETFs.
  • Distributions for the ETFs (if any) are variable and may vary significantly from month to month and may be zero.
  • If the Fund does make distributions, the amounts of such distributions will likely vary greatly from one distribution to the next.

YieldMax™ ETFs Announces Monthly Distributions on AMDY (65.22%), CONY (58.23%), TSLY (57.79%), DISO (42.66%), PYPY (38.82%) and Others

Retrieved on: 
Tuesday, November 7, 2023
ARK, COIN, SQ, NVDA, Funding, Investment, MRNA, Risk, NAV, Capital gain, Sale, Unitary state, GOOGL, TSLA, AMD, GOOY, Lovell Minnick Partners, Trust, META, JPM, Government, PYPL, AAPL, History, AMZN, MSFT, Adviser, XOM, AND, Option contract, O'Hara, U.S. Treasury, NFLX, ETF, TRUST, 7-day SEC yield, Falmouth Foreside, Maine, Prospectus, DIS, Life insurance, Security (finance), Telescopic sight, Financial adviser, Fund

The Distribution Rate is calculated by multiplying an ETF’s Distribution per Share by twelve (12), and dividing the resulting amount by the ETF’s most recent NAV.

Key Points: 
  • The Distribution Rate is calculated by multiplying an ETF’s Distribution per Share by twelve (12), and dividing the resulting amount by the ETF’s most recent NAV.
  • The Distribution Rate and 30-Day SEC Yield are not indicative of future distributions, if any, on the ETFs.
  • Distributions for the ETFs (if any) are variable and may vary significantly from month to month and may be zero.
  • If the Fund does make distributions, the amounts of such distributions will likely vary greatly from one distribution to the next.